Search Results - "Fleischmann, RM"

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate by Weinblatt, Michael E, Kremer, Joel M, Bankhurst, Arthur D, Bulpitt, Ken J, Fleischmann, Roy M, Fox, Robert I, Jackson, Christopher G, Lange, Mary, Burge, Daniel J

“…Among the disease-modifying drugs used to treat rheumatoid arthritis, methotrexate is increasingly regarded as the agent of first choice, because of its early…”
Get full text

Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial by Fleischmann, R. M., Cohen, S. B., Moreland, L. W., Schiff, M., Mease, P. J., Smith, D. B., Keenan, G., Kremer, J. M.

“…ABSTRACT Objective: Infliximab plus methotrexate (MTX) is approved for the treatment of rheumatoid arthritis (RA). Based on the benefit/risk profile of this…”
Get full text

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years by van Vollenhoven, Ronald F, Fleischmann, Roy M, Furst, Daniel E, Lacey, Stuart, Lehane, Patricia B

“…Final evaluation of the longterm safety of rituximab (RTX) in rheumatoid arthritis (RA) up to 11 years. Pooled observed case analysis of data from patients…”
Get full text

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients by van Vollenhoven, Ronald F, Emery, Paul, Bingham, 3rd, Clifton O, Keystone, Edward C, Fleischmann, Roy M, Furst, Daniel E, Tyson, Nicola, Collinson, Neil, Lehane, Patricia B

“…Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA). Pooled observed case analysis of data from patients with moderate-to-severe, active…”
Get more information

Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: Focus on etanercept, a new biologic response modifier by Fleischmann, Roy M.

“…Early diagnosis and prompt treatment can improve outcomes in rheumatoid arthritis (RA). Significant joint damage occurs early in the course of the disease,…”
Get full text

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) by FURST, Daniel E, SCHIFF, Michael H, FLEISCHMANN, Roy M, STRAND, Vibeke, BIRBARA, Charles A, COMPAGNONE, Daniele, FISCHKOFF, Steven A, CHARTASH, Elliot K

“…OBJECTIVE: This study, known as STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), evaluated the safety and efficacy of adalimumab (Humira), a fully…”
Get full text

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis by Bathon, Joan M, Martin, Richard W, Fleischmann, Roy M, Tesser, John R, Schiff, Michael H, Keystone, Edward C, Genovese, Mark C, Wasko, Mary Chester, Moreland, Larry W, Weaver, Arthur L, Markenson, Joseph, Finck, Barbara K

“…Etanercept (Enbrel, Immunex, Seattle) is a soluble tumor necrosis factor (TNF) receptor fusion protein that binds and inactivates TNF, a proinflammatory…”
Get full text

A double-masked comparison of naprelan ® and nabumetone in osteoarthritis of the knee by Fleischmann, Roy M, Fling, Kathleen, Constantine, Ginger, Kolecki, Barbara

“…The efficacy and safety of Naprelan ® (naproxen sodium) 1000 mg once daily (QD) and nabumetone 1500 mg QD were compared in a multicenter, randomized,…”
Get full text

Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation by Roth, S H, Fleischmann, R M, Burch, F X, Dietz, F, Bockow, B, Rapoport, R J, Rutstein, J, Lacouture, P G

“…Although opioid analgesics have well-defined efficacy and safety in treatment of chronic cancer pain, further research is needed to define their role in…”
Get more information

Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial by MORELAND, L. W, SCHIFF, M. H, RUDERMAN, E. M, HORWITZ, D. A, ARKFELD, D. G, GARRISON, L, BURGE, D. J, BLOSCH, C. M, LANGE, M. L. M, MCDONNELL, N. D, WEINBLATT, M. E, BAUMGARTNER, S. W, TINDALL, E. A, FLEISCHMANN, R. M, BULPITT, K. J, WEAVER, A. L, KEYSTONE, E. C, FURST, D. E, MEASE, P. J

“…In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in…”
Get full text

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis by BATHON, Joan M, FLEISCHMANN, Roy M, VAN DER HEIJDE, Désirée M, TESSER, John R, PELOSO, Paul M, CHON, Yun, WHITE, Barbara

“…OBJECTIVE: To evaluate safety and efficacy of etanercept treatment in elderly (age > or = 65 yrs) and younger adult subjects (age < 65 yrs) with rheumatoid…”
Get full text

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis by GENOVESE, Mark C, BATHON, Joan M, FLEISCHMANN, Roy M, MORELAND, Larry W, MARTIN, Richard W, WHITMORE, James B, TSUJI, Wayne H, LEFF, Jonathan A

“…OBJECTIVE: To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with…”
Get full text

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein by Moreland, Larry W, Baumgartner, Scott W, Schiff, Michael H, Tindall, Elizabeth A, Fleischmann, Roy M, Weaver, Arthur L, Ettlinger, Robert E, Cohen, Stanley, Koopman, William J, Mohler, Kendall, Widmer, Michael B, Blosch, Consuelo M

“…Rheumatoid arthritis is a common disease, and it produces substantial morbidity as well as an increase in mortality. 1 – 4 Although the causes of rheumatoid…”
Get full text

Is there a need for new therapies for rheumatoid arthritis? by Fleischmann, Roy M

“…Although traditional disease modifying and biological response modifying agents are very useful in controlling disease activity, limiting disease progression,…”
Get more information

Addressing the safety of anakinra in patients with rheumatoid arthritis by Fleischmann, R M

“…Anakinra (Kineret®; Amgen Inc., Thousand Oaks, CA) is the first and only recombinant human interleukin-1 receptor antagonist available for therapeutic use. It…”
Get full text

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability by BAUMGARTNER, Scott W, FLEISCHMANN, Roy M, MORELAND, Larry W, SCHIFF, Michael H, MARKENSON, Joseph, WHITMORE, James B

“…OBJECTIVE: To compare etanercept-induced improvement in disability of patients with recent onset of rheumatoid arthritis (RA) to that of patients with…”
Get full text

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results by FLEISCHMANN, Roy M, BAUMGARTNER, Scott W, TINDALL, Elizabeth A, WEAVER, Arthur L, MORELAND, Larry W, SCHIFF, Michael H, MARTIN, Richard W, SPENCER-GREEN, George T

“…OBJECTIVE: Approximately 3% of the US population over the age of 65 years has rheumatoid arthritis (RA). We compared the safety and efficacy of etanercept…”
Get full text

Examining the efficacy of biologic therapy: are there real differences? by Fleischmann, Roy M

“…Biologic therapy with anakinra, etanercept, and infliximab effectively reduced the signs and symptoms of active rheumatoid arthritis (RA) in randomized…”
Get more information

LONG-TERM SAFETY OF RITUXIMAB: POOLED ANALYSIS OF THE RHEUMATOID ARTHRITIS GLOBAL CLINICAL TRIAL PROGRAMME OVER 11 YEARS by van Vollenhoven, RF, Emery, P, Bingham, CO, Keystone, E, Fleischmann, RM, Furst, DE, Hessey, EW, Mehbob, A, Lehane, PB

Get full text

Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. Nabumetone versus naproxen double-blind parallel study by Vasey, F B, Germain, B F, Espinoza, L R, Box, P, Bockow, B I, Lipani, J A, Mullen, B J, Brodsky, A L, Fleischmann, R M, Fogari, R A

“…Nabumetone is a new nonsteroidal anti-inflammatory agent. Therapy with nabumetone 1,000 mg given at bedtime was compared with naproxen 250 mg given twice daily…”
Get more information